India's Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients
Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.
No comments:
Post a Comment